Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Description
Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major mesothelioma markets reached a value of US$ 434.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 905.6 Million by 2034, exhibiting a growth rate (CAGR) of 6.91% during 2024-2034.
The mesothelioma market has been comprehensively analyzed in IMARC's new report titled "Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mesothelioma refers to a type of cancer that affects the thin layer of tissue (mesothelium) covering the internal organs of the body. The symptoms of the ailment can vary depending on the location of the cancer, but the most common form, pleural mesothelioma, typically presents with indications like coughing, chest pain, shortness of breath, etc. Numerous other manifestations may include fatigue, weight loss, difficulty swallowing, etc. In some cases, patients may also experience abdominal pain and swelling. A definitive diagnosis of the disease can be challenging due to its similarity to other conditions, so a comprehensive evaluation by an experienced team is essential for an accurate prognosis. The diagnostic process may include imaging procedures, such as X-rays, CT scans, MRIs, etc., as well as biopsies to examine tissue samples for signs of cancer. Doctors may also perform pulmonary function tests to evaluate lung function and blood tests to look for biomarkers associated with mesothelioma.
The increasing cases of exposure to asbestos fibers, which become lodged in the lining of the lungs, abdomen, or heart, and cause irritation as well as inflammation, are primarily driving the mesothelioma market. Besides this, the widespread adoption of pleurectomy with decortication for relieving symptoms, such as chest pain and difficulty breathing, and improving survival rates in patients is also propelling the market growth. Furthermore, the escalating utilization of chemotherapy in combination with various other treatments, including surgery or radiation therapy, to shrink tumor size and slow the progression of mesothelioma is acting as another significant growth-inducing factor. Additionally, several key players are making extensive investments in R&D activities to introduce targeted therapies that target specific molecules or pathways involved in the formation and spread of cancer cells. This, in turn, is also creating a positive outlook for the market. Moreover, the introduction of high-resolution CT scanning for detecting abnormalities in the lungs or pleura, which may be indicative of the disease, is expected to drive the mesothelioma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the mesothelioma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mesothelioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mesothelioma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mesothelioma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mesothelioma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mesothelioma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the mesothelioma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mesothelioma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mesothelioma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of mesothelioma across the seven major markets?
What is the number of prevalent cases (2018-2034) of mesothelioma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mesothelioma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with mesothelioma across the seven major markets?
What is the size of the mesothelioma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mesothelioma?
What will be the growth rate of patients across the seven major markets?
Mesothelioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mesothelioma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mesothelioma market?
What are the key regulatory events related to the mesothelioma market?
What is the structure of clinical trial landscape by status related to the mesothelioma market?
What is the structure of clinical trial landscape by phase related to the mesothelioma market?
What is the structure of clinical trial landscape by route of administration related to the mesothelioma market?
Table of Contents
133 Pages
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Mesothelioma - Introduction
- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence
- 5 Mesothelioma - Disease Overview
- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment
- 6 Patient Journey
- 7 Mesothelioma - Epidemiology and Patient Population
- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
- 7.2.1 Epidemiology Scenario (2018-2023)
- 7.2.2 Epidemiology Forecast (2024-2034)
- 7.2.3 Epidemiology by Age (2018-2034)
- 7.2.4 Epidemiology by Gender (2018-2034)
- 7.2.5 Epidemiology by Type (2018-2034)
- 7.2.6 Diagnosed Cases (2018-2034)
- 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
- 7.3.1 Epidemiology Scenario (2018-2023)
- 7.3.2 Epidemiology Forecast (2024-2034)
- 7.3.3 Epidemiology by Age (2018-2034)
- 7.3.4 Epidemiology by Gender (2018-2034)
- 7.3.5 Epidemiology by Type (2018-2034)
- 7.3.6 Diagnosed Cases (2018-2034)
- 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
- 7.4.1 Epidemiology Scenario (2018-2023)
- 7.4.2 Epidemiology Forecast (2024-2034)
- 7.4.3 Epidemiology by Age (2018-2034)
- 7.4.4 Epidemiology by Gender (2018-2034)
- 7.4.5 Epidemiology by Type (2018-2034)
- 7.4.6 Diagnosed Cases (2018-2034)
- 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
- 7.5.1 Epidemiology Scenario (2018-2023)
- 7.5.2 Epidemiology Forecast (2024-2034)
- 7.5.3 Epidemiology by Age (2018-2034)
- 7.5.4 Epidemiology by Gender (2018-2034)
- 7.5.5 Epidemiology by Type (2018-2034)
- 7.5.6 Diagnosed Cases (2018-2034)
- 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
- 7.6.1 Epidemiology Scenario (2018-2023)
- 7.6.2 Epidemiology Forecast (2024-2034)
- 7.6.3 Epidemiology by Age (2018-2034)
- 7.6.4 Epidemiology by Gender (2018-2034)
- 7.6.5 Epidemiology by Type (2018-2034)
- 7.6.6 Diagnosed Cases (2018-2034)
- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
- 7.7.1 Epidemiology Scenario (2018-2023)
- 7.7.2 Epidemiology Forecast (2024-2034)
- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Epidemiology by Type (2018-2034)
- 7.7.6 Diagnosed Cases (2018-2034)
- 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
- 7.8.1 Epidemiology Scenario (2018-2023)
- 7.8.2 Epidemiology Forecast (2024-2034)
- 7.8.3 Epidemiology by Age (2018-2034)
- 7.8.4 Epidemiology by Gender (2018-2034)
- 7.8.5 Epidemiology by Type (2018-2034)
- 7.8.6 Diagnosed Cases (2018-2034)
- 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
- 7.9.1 Epidemiology Scenario (2018-2023)
- 7.9.2 Epidemiology Forecast (2024-2034)
- 7.9.3 Epidemiology by Age (2018-2034)
- 7.9.4 Epidemiology by Gender (2018-2034)
- 7.9.5 Epidemiology by Type (2018-2034)
- 7.9.6 Diagnosed Cases (2018-2034)
- 7.9.7 Patient Pool/Treated Cases (2018-2034)
- 8 Mesothelioma - Treatment Algorithm, Guidelines, and Medical Practices
- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm
- 9 Mesothelioma - Unmet Needs
- 10 Mesothelioma - Key Endpoints of Treatment
- 11 Mesothelioma - Marketed Products
- 11.1 List of Mesothelioma Marketed Drugs Across the Top 7 Markets
- 11.1.1 Alimta (Pemetrexed) - Eli Lilly and Company
- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets
- 11.1.2 Yervoy (Ipilimumab) - Bristol Myers Squibb
- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Opdivo (Nivolumab) - Bristol-Myers Squibb/Ono Pharmaceuticals
- 11.1.3.1 Drug Overview
- 11.1.3.2 Mechanism of Action
- 11.1.3.3 Regulatory Status
- 11.1.3.4 Clinical Trial Results
- 11.1.3.5 Sales Across Major Markets
- Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
- 12 Mesothelioma - Pipeline Drugs
- 12.1 List of Mesothelioma Pipeline Drugs Across the Top 7 Markets
- 12.1.1 MTG 201 - Momotaro-Gene
- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 IAG933 - Novartis Pharmaceuticals
- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 RSO 021 - RS Oncology
- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status
- 12.1.4 MesoPher - Amphera
- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status
- 12.1.5 SAR444245 - Sanofi
- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results
- 12.1.5.4 Safety and Efficacy
- 12.1.5.5 Regulatory Status
- Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
- 13. Mesothelioma - Attribute Analysis of Key Marketed and Pipeline Drugs
- 14. Mesothelioma – Clinical Trial Landscape
- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events
- 15 Mesothelioma - Market Scenario
- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
- 15.2.1 Mesothelioma - Market Size
- 15.2.1.1 Market Size (2018-2023)
- 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Mesothelioma - Market Size by Therapies
- 15.2.2.1 Market Size by Therapies (2018-2023)
- 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
- 15.3.1 Mesothelioma - Market Size
- 15.3.1.1 Market Size (2018-2023)
- 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Mesothelioma - Market Size by Therapies
- 15.3.2.1 Market Size by Therapies (2018-2023)
- 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Mesothelioma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
- 15.4.1 Mesothelioma - Market Size
- 15.4.1.1 Market Size (2018-2023)
- 15.4.1.2 Market Forecast (2024-2034)
- 15.4.2 Mesothelioma - Market Size by Therapies
- 15.4.2.1 Market Size by Therapies (2018-2023)
- 15.4.2.2 Market Forecast by Therapies (2024-2034)
- 15.4.3 Mesothelioma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
- 15.5.1 Mesothelioma - Market Size
- 15.5.1.1 Market Size (2018-2023)
- 15.5.1.2 Market Forecast (2024-2034)
- 15.5.2 Mesothelioma - Market Size by Therapies
- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Mesothelioma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
- 15.6.1 Mesothelioma - Market Size
- 15.6.1.1 Market Size (2018-2023)
- 15.6.1.2 Market Forecast (2024-2034)
- 15.6.2 Mesothelioma - Market Size by Therapies
- 15.6.2.1 Market Size by Therapies (2018-2023)
- 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Mesothelioma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
- 15.7.1 Mesothelioma - Market Size
- 15.7.1.1 Market Size (2018-2023)
- 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Mesothelioma - Market Size by Therapies
- 15.7.2.1 Market Size by Therapies (2018-2023)
- 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Mesothelioma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
- 15.8.1 Mesothelioma - Market Size
- 15.8.1.1 Market Size (2018-2023)
- 15.8.1.2 Market Forecast (2024-2034)
- 15.8.2 Mesothelioma - Market Size by Therapies
- 15.8.2.1 Market Size by Therapies (2018-2023)
- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Mesothelioma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
- 15.9.1 Mesothelioma - Market Size
- 15.9.1.1 Market Size (2018-2023)
- 15.9.1.2 Market Forecast (2024-2034)
- 15.9.2 Mesothelioma - Market Size by Therapies
- 15.9.2.1 Market Size by Therapies (2018-2023)
- 15.9.2.2 Market Forecast by Therapies (2024-2034)
- 15.9.3 Mesothelioma - Access and Reimbursement Overview
- 16 Mesothelioma - Recent Events and Inputs From Key Opinion Leaders
- 17 Mesothelioma Market - SWOT Analysis
- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats
- 18 Mesothelioma Market – Strategic Recommendations
- 19 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
